Answers are grounded in this paper and cite their sources.
Our results suggest that high expression of CAF-related biomarkers, particularly PDGFR-β and α-SMA, is associated with poor prognosis and recurrence in patients with BM. With the elucidation of the role and origins of CAF in the tumor microenvironment, CAF can be a new imperative target for BM immunotherapy.
No takes yet. Share an insight, caveat, or question.
Akanda et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: